Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  Brainstorm Cell Therapeutics Inc    

BRAINSTORM CELL THERAPEUTICS INC
Mes dernières consult.
Most popular
  Report  
SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Brainstorm Cell Therapeutics Inc : BrainStorm Announces CEO Interview with the Wall Street Analyst

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/23/2013 | 05:03pm CEST

BrainStorm Announces CEO Interview with the Wall Street Analyst

New York, NY and Petach Tikvah, Israel, May 23, 2013 - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that The Wall Street Analyst conducted an audio interview yesterday with the Company's Chief Executive Officer, Alon Natanson. The interview can be heard on The Wall Street Analyst website at the following link: http://thewallstreetanalysts.com/brainstorm-cell-therapeutics-otcqbbcli-ceo-interview.

Topics discussed by Mr. Natanson include an update on the Company's NurOwn™ stem cell technology and its use in current and upcoming clinical trial activities. Specifically, Mr. Natanson discussed the very encouraging observations in the Company's recently completed Phase I/II trial, advances in the ongoing Phase IIa clinical trial and plans for the upcoming Phase II trial, expected to begin later this year in the U.S. at sites including Massachusetts General Hospital, UMass Hospital and the Mayo Clinic.

During the interview Mr. Natanson commented, "As far as companies in this field go, I think we've progressed more quickly than anyone, having successfully completed a Phase I trial in only a year and a half, and moved ahead immediately to Phase II, which should conclude later this year. To achieve all this in only 2 ½ years is extremely fast. We hope to run our upcoming US trial at an equally fast pace, as we feel we are in a race to beat this disease and get our product to the market as quickly as possible."

About The Wall Street Analyst

The Wall Street Analyst conducts unbiased, unfiltered and candid interviews with management of publicly traded companies to unlock possible investment opportunities before the rest of the market discovers them. The WSA's staff of writers, analysts, publishers, producers, market researchers and PR professionals aim to provide investors with the tools they need to make informed decisions on buying stock and its audience consists of retail and institutional investors, analysts, fund managers and members of the financial press. For more information, visit www.thewallstreetanalysts.com.

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company's website at www.brainstorm-cell.com.

Safe Harbor Statement - Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

BrainStorm Cell Therapeutics Inc. LifeSci Advisors, LLC

Mr. Alon Natanson, CEO Michael Rice, Founding Partner

Phone: +972-3-9236384 Phone: 646-597-6979

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRAINSTORM CELL THERAPEUTI
04/11BRAINSTORM CELL THERAPEUTICS : to Present at ARM's 6th Annual Cell & Gene Therap..
PU
04/09BRAINSTORM CELL THERAPEUTICS : Letter To Shareholders
PU
03/29BRAINSTORM CELL THERAPEUTICS : Appoints Two Leading Thought Leaders in the Field..
AQ
03/20INSIDER TRADING ACTIVITY BRAINSTORM : BCLI) – COO Bought 5,000 shares of ..
AQ
03/20INSIDER TRADING ACTIVITY BRAINSTORM : BCLI) – Director Bought 5,700 share..
AQ
03/08BRAINSTORM CELL THERAPEUTICS INC : Brainstorm Cell Therapeutics Inc. to Host Ear..
AC
03/08BRAINSTORM CELL THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL..
AQ
02/15BRAINSTORM CELL THERAPEUTICS : Appoints Senior Kite Executive, Anthony Polverino..
AQ
02/07BRAINSTORM CELL THERAPEUTICS : NurOwn® Phase 2 ALS Clinical Trial and Biomarker ..
PU
02/06BRAINSTORM CELL THERAPEUTICS INC. (N : BCLI) Files An 8-K Departure of Directors..
AQ
More news
Financials ($)
Sales 2018 -
EBIT 2018 -30,0 M
Net income 2018 -30,0 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 0
Capi. / Sales 2019 0
Capitalization 64,6 M
Chart BRAINSTORM CELL THERAPEUTI
Duration : Period :
Brainstorm Cell Therapeuti Technical Analysis Chart | US10501E1029 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 9,00 $
Spread / Average Target 161%
EPS Revisions
Managers
NameTitle
Chaim Lebovits President & Chief Executive Officer
Jerold Chun Chairman
Ralph Z. Kern Chief Operating & Medical Officer
Eyal Rubin Chief Financial Officer & Treasurer
Yael Gothelf Vice President-Scientific & Regulatory Affairs
Sector and Competitors
1st jan.Capitalization (M$)
BRAINSTORM CELL THERAPEUTICS INC65
CELLTRION, INC.--.--%31 274
IQVIA HOLDINGS INC0.17%20 671
LONZA GROUP-6.84%18 497
NEKTAR THERAPEUTICS56.92%14 892
INCYTE CORPORATION-26.02%14 841